ESMO Handbook of Immuno-Oncology

2018 ESMO Handbook for Immuno-Oncology Cover

Download the complete book (ESMO Members only)

Take the handbook CME test (ESMO Members only)

Watch the video presenting the Handbook by John B.A.G. Haanen , co-editor of the ESMO Handbook of Immuno-oncology.

Over the past decade, the field of immuno-oncology has truly come of age and is rapidly evolving. Within just a few years, immunotherapy has been approved as an important treatment option for patients across many cancer types.The ESMO Handbook of Immuno-Oncology was written by specialists in the field and covers many aspects of immuno-oncology, from basic immunology to the current state-of-the-art clinical immunotherapy in different disease types, including management of immune-related toxicities.This comprehensive overview provides a strong base to understand the theory, mechanisms of action, clinical developments and the future of immuno-oncology, and, therefore, is a “must read” for any professional involved in the care of cancer patients.

Section 1: Introduction to immunology and immunotherapy

1.1 Immune Checkpoints

1.2 Adoptive T Cell Therapy

1.3 Vaccines (Dendritic Cell Vaccines, Peptide Vaccines, DNA Vaccines, RNA Vaccines, Oncolytic Viruses)

1.4 Biomarkers for Immunotherapy

1.5 Resistance to Immunotherapy

Section 2: Immunotherapies in specific disease groups –  State of the art

2.1 Melanoma

2.2 Merkel Cell Carcinoma

2.3 Thoracic Malignancies

2.3.1 Non-small Cell Lung Cancer

2.3.2 Small Cell Lung Cancer

2.3.3 Mesothelioma

2.3.4 Other Thoracic Malignancies: Thymic Malignancies and Others

2.4 Genitourinary Malignancies

2.4.1 Renal Cancer

2.4.2 Bladder Cancer

2.5 Gastrointestinal Malignancies

2.5.1 Microsatellite Instability-high

2.5.2 Gastric and Oesophageal Malignancies

2.5.3. Hepatocellular Carcinoma

2.6 Immunotherapy in Head and Neck Tumours (HPV+ and HPV-)

2.7 Immunotherapies in Lymphoma

2.8 Gynaecological Malignancies

Section 3: Implications for clinical practice

3.1 Management of Adverse Events Related to Immune Checkpoint Blockade

3.2 Immune Checkpoint Blockade: Response Patterns and Assessment of Response

3.3 Immunotherapy in Special Populations

3.4 Cancer Immunotherapy Trials: Challenges and Opportunities

3.5 Future Perspectives